Literature DB >> 1855120

Characterization of Gaddum's substance R.

G J Douglas1, K I Williams, R J Flower.   

Abstract

1. When the isolated small intestine of the rat is perfused via the mesenteric artery, an oxytocic principle (Gaddum's substance R) is released which is detectable in the perfusate after 30 min and is present in samples collected 8 h later. 2. The oxytocic activity of substance R is lost after boiling but is unaffected by treatment with thioglycolate. Furthermore, atropine, methysergide and indomethacin failed to antagonize uterine contractions to substance R. 3. Neither substance R nor urinary kallikrein alone induce a contraction of the guinea-pig isolated ileum. However, in the presence of kininogen both substance R and urinary kallikrein produce a slow and prolonged contraction of the guinea-pig ileum. 4. The oxytocic and kininogenase properties of both substance R and urinary kallikrein are inhibited by Trasylol. 5. Soy bean trypsin inhibitor (SBTI) selectively inhibited both the oxytocic and the kininogenase activities of substance R but not those of urinary kallikrein. 6. Gel filtration of substance R resolved a single peak of oxytocic activity with an estimated molecular weight of 40 kDa. 7. We conclude that substance R is a kininogenase enzyme which may be distinguished from plasma kallikrein by its molecular weight and from urinary kallikrein by its susceptibility to SBTI. The exact nature of this enzyme remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855120      PMCID: PMC1917980          DOI: 10.1111/j.1476-5381.1991.tb12278.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  The technique of superfusion.

Authors:  J H GADDUM
Journal:  Br J Pharmacol Chemother       Date:  1953-09

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  New synthetic antagonists of bradykinin.

Authors:  M Schachter; Y Uchida; D J Longridge; T Labedz; E T Whalley; R J Vavrek; J M Stewart
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

4.  Effect of inhibitors on kinin-releasing activity of proteases.

Authors:  N Back; R Steger
Journal:  Fed Proc       Date:  1968 Jan-Feb

5.  Sensitization of guinea-pig ileum to the action of bradykinin by trypsin hydrolysate of ox and rabbit plasma.

Authors:  P N Aarsen
Journal:  Br J Pharmacol Chemother       Date:  1968-03

6.  Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein.

Authors:  H Nolly; A G Scicli; G Scicli; O A Carretero
Journal:  Circ Res       Date:  1985-06       Impact factor: 17.367

7.  Kinins contribute to the contractile effects of rat glandular kallikrein on the isolated rat uterus.

Authors:  G G Orce; O A Carretero; G Scicli; A G Scicli
Journal:  J Pharmacol Exp Ther       Date:  1989-05       Impact factor: 4.030

8.  Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats.

Authors:  M F Sim; D B Yates; R Parkinson; M J Cooling
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

9.  The actions of kinin antagonists on B1 and B2 receptor systems.

Authors:  D Regoli; G Drapeau; P Rovero; S Dion; P D'Orléans-Juste; J Barabé
Journal:  Eur J Pharmacol       Date:  1986-04-09       Impact factor: 4.432

10.  Kininogenase from rat vascular tissue.

Authors:  H Nolly; A G Scicli; G Scicli; M C Lama; A M Guercio; O A Carretero
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.